ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions
View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM
Abstract Number: 2145
Long-term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Incidence of Severe Infections Through 3 Years (148 Weeks) from 2 Phase 3 Trials
Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies
9:00AM-11:00AM
Abstract Number: 2347
Long-term Survival in Lung Transplantation and Allograft Rejection in Patients with Interstitial Lung Disease Related with Rheumatoid Arthritis: Study from a Single Referral Center
RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities
9:00AM-11:00AM
Abstract Number: 2592
Longitudinal Changes in Health-related Quality of Life in Systemic Sclerosis Treated with Autologous Hematopoietic Stem Cell Transplant Compared to Standard of Care
Systemic Sclerosis & Related Disorders – Clinical Poster III
9:00AM-11:00AM
Abstract Number: 2014
Loss-of-function of the DNA Repair Nuclease MRE11A Induces Mitochondrial Failure and Tissue Inflammation in Rheumatoid Arthritis
RA – Etiology & Pathogenesis Poster II
9:00AM-11:00AM
Abstract Number: 2413
LOU064: A Highly Selective and Potent Covalent Oral BTK Inhibitor with Promising Pharmacodynamic Efficacy on B Cells for Sjoegren’s Syndrome
Sjögrenʼs Syndrome – Basic & Clinical Science Poster I
9:00AM-11:00AM
Abstract Number: 2531
Low Vitamin D Is Associated with Miscarriage and Preterm Birth in SLE with a U-shaped Relationship
SLE – Clinical Poster III: Treatment
9:00AM-11:00AM
Abstract Number: 2164
Lumbar Spinal Stenosis in Patients with Wild-type Transthyretin Cardiac Amyloidosis
Orthopedics, Low Back Pain, & Rehabilitation Poster – ACR/ARP
9:00AM-11:00AM
Abstract Number: 2312
Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis: Results from Japanese Multi-institutional Study Using Research Electronic Data Capture
RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities
9:00AM-11:00AM
Abstract Number: 2196
Machine Learning Defines the Relationship Between Structural Knee Osteoarthritis and Patient-Important Outcomes: An 8-year Study of 47,858 Knee MRIs from the Osteoarthritis Initiative (OAI)
Osteoarthritis – Clinical Poster II
9:00AM-11:00AM
Abstract Number: 2200
Magnetic Resonance Imaging of Knee Joint Protection Following an Intra-Articular Injection of Lipid-Based Dexamethasone Sodium Phosphate Sustained Release Formulation on Subjects with Knee Osteoarthritis
Osteoarthritis – Clinical Poster II
9:00AM-11:00AM
Abstract Number: 2663
Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial
Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis
9:00AM-11:00AM
Abstract Number: L11
Maintenance of Remission Following Dose De-Escalation of Abatacept in Early, MTX-Naïve, ACPA-Positive Patients with RA: Results from a Randomized Phase IIIb Study
Late-Breaking Abstracts ePoster
9:00AM-11:00AM
Abstract Number: 1998
Major Histocompatibility Antigen HLA-DQB1*0601 Is Associated with Rheumatoid Arthritis Among Indians in a Replication Study: Evidence of Gene-Environment Interaction with LPG Stove Use
RA – Etiology & Pathogenesis Poster II
9:00AM-11:00AM
Abstract Number: 2269
Major Stressors in the Year Prior to Diagnosis Affects RA Characteristics at Presentation and 1 Year
Psychology/Social Science Poster – ARP
9:00AM-11:00AM
Abstract Number: 2584
Management of Cutaneous Manifestations of Lupus Erythematosus: A Systematic Review
SLE – Clinical Poster III: Treatment
  • «Previous Page
  • 1
  • …
  • 28
  • 29
  • 30
  • 31
  • 32
  • …
  • 64
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology